Well-differentiated neuroendocrine tumors with a morphologically apparent high-grade component: A pathway distinct from poorly differentiated neuroendocrine carcinomas

Clinical Cancer Research

Volumn 22, Issue 4, 2016, Pages 1011-1017

  Tang, Laura H ^a   Untch, Brian R ^a   Reidy, Diane L ^a   O'Reilly, Eileen ^a   Dhall, Deepti ^b   Jih, Lily ^b   Basturk, Olca ^a   Allen, Peter J ^a   Klimstra, David S ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER;

ADULT; AGED; ARTICLE; BILE DUCT; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER GROWTH; CANCER LOCALIZATION; CANCER MORPHOLOGY; CANCER SPECIFIC SURVIVAL; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE SPECIFIC SURVIVAL; FEMALE; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR; GENE MUTATION; GENOTYPE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; METASTASIS; MUTATIONAL ANALYSIS; PANCREAS; PHENOTYPE; POORLY DIFFERENTIATED NEUROENDOCRINE CARCINOMA; PRIMARY TUMOR; PRIORITY JOURNAL; RADIODIAGNOSIS; RECTUM; RETROSPECTIVE STUDY; SMALL INTESTINE; SURVIVAL TIME; WELL DIFFERENTIATED NEUROENDOCRINE TUMOR; DNA MUTATIONAL ANALYSIS; FOLLOW UP; GENETICS; MIDDLE AGED; MORTALITY; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; TREATMENT OUTCOME;

AGED; DNA MUTATIONAL ANALYSIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84964476030     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-0548     Document Type: Article

References (27)

1. Niederle MB, Hackl M, Kaserer K, Niederle B. Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters. ERC 2010;17:909-18.
2. Kloppel G. Classification and pathology of gastroenteropancreatic neuroendocrine neoplasms. ERC 2011;18 Suppl 1:S1-16.
3. Hochwald SN, Zee S, Conlon KC, Colleoni R, Louie O, Brennan MF, et al. Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. JCO 2002;20:2633-42.
4. Ferrone CR, Tang LH, Tomlinson J, Gonen M, Hochwald SN, Brennan MF, et al. Determining prognosis in patients with pancreatic endocrine neoplasms: can the WHO classification system be simplified? JCO 2007;25: 5609-15.
5. Liu TC, Hamilton N, Hawkins W, Gao F, Cao D. Comparison of WHO Classifications (2004, 2010), the Hochwald grading system, and AJCC and ENETS staging systems in predicting prognosis in locoregional well-differentiated pancreatic neuroendocrine tumors. AJSP 2013;37:853-9.
6. Rindi G, Klöppel G, Alhman H, Caplin M, Couvelard A, de Herder WW, et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2006;449:395-401.
7. Bosman FT CF, Hruban RH, Theise ND. World Health Organization (WHO) classification of tumours of the digestive system. Geneva, Switzerland: WHO Press; 2010.
8. Yachida S, Vakiani E, White CM, Zhong Y, Saunders T, Morgan R, et al. Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors. AJSP 2012;36:173-84.
9. Sorbye H, Welin S, Langer SW, Vestermark LW, Holt N, Osterlund P, et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann Oncol 2013;24:152-60.
10. Shia J, Tang LH, Weiser MR, Brenner B, Adsay NV, Stelow EB, et al. Is nonsmall cell type high-grade neuroendocrine carcinoma of the tubular gastrointestinal tract a distinct disease entity? AJSP 2008;32:719-31.
11. Brenner B, Tang LH, Shia J, Klimstra DS, Kelsen DP. Small cell carcinomas of the gastrointestinal tract: clinicopathological features and treatment approach. Semin Oncol 2007;34:43-50.
12. Basturk O, Tang L, Hruban RH, Adsay V, Yang Z, Krasinskas AM, et al. Poorly differentiated neuroendocrine carcinomas of the pancreas: a clinicopathologic analysis of 44 cases. AJSP 2014;38:437-47.
13. Vélayoudom-Céphise FL, Duvillard P, Foucan L, Hadoux J, Chougnet CN, Leboulleux S, et al. Are G3 ENETS neuroendocrine neoplasms heterogeneous? ECR 2013;20:649-57.
14. Yang Z, Tang LH, Klimstra DS. Effect of tumor heterogeneity on the assessment of Ki67 labeling index in well-differentiated neuroendocrine tumors metastatic to the liver: implications for prognostic stratification. AJSP 2011;35:853-60.
15. Jiao Y, Shi C, Edil BH, de Wilde RF, Klimstra DS, Maitra A, et al. DAXX/ ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 2011;331: 1199-203.
16. Masson P. Carcinoids (Argentaffin-Cell Tumors) and Nerve Hyperplasia of the Appendicular Mucosa. AJP 1928;4:181-212.19.
17. Rosai J. The origin of neuroendocrine tumors and the neural crest saga. Mod Pathol 2011;24 Suppl 2:S53-7.
18. Oberg K. Circulating biomarkers in gastroenteropancreatic neuroendocrine tumours. ECC 2011;18 Suppl 1:S17-25.
19. Lawrence B, Gustafsson BI, Kidd M, Pavel M, Svejda B, Modlin IM. The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am 2011;40:111-34.
20. Reubi JC, Schär JC, Waser B, Wenger S, Heppeler A, Schmitt JS, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. EJNMMI 2000;27:273-82.
21. Treglia G, Castaldi P, Rindi G, Giordano A, Rufini V. Diagnostic performance of Gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis. Endocrine 2012;42:80-7.
22. Velikyan I, Sundin A, Sörensen J, Lubberink M, Sandström M, Garske-Román U, et al. Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification. J Nucl Med 2014;55:204-10.
23. Toumpanakis C, Kim MK, Rinke A, Bergestuen DS, Thirlwell C, Khan MS, et al. Combination of cross-sectional and molecular imaging studies in the localization of gastroenteropancreatic neuroendocrine tumors. Neuroendocrinology 2014;99:63-74.
24. Sorbye H, Strosberg J, Baudin E, Klimstra DS, Yao JC. Gastroenteropancreatic high-grade neuroendocrine carcinoma. Cancer 2014;120:2814-23.
25. Basturk O, Yang Z, Tang LH, Hruban RH, Adsay V, McCall CM, et al. The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogeneous and includes both well differentiated and poorly differentiated neoplasms. AJSP 2015;39:683-90.
26. McCall CM, Shi C, Cornish TC, Klimstra DS, Tang LH, Basturk O, et al. Grading of well-differentiated pancreatic neuroendocrine tumors is improved by the inclusion of both Ki67 proliferative index and mitotic rate. AJSP 2013;37:1671-7.
27. Tang LH, Gonen M, Hedvat C, Modlin IM, Klimstra DS. Objective quantification of the Ki67 proliferative index in neuroendocrine tumors of the gastroenteropancreatic system: a comparison of digital image analysis with manual methods. AJSP 2012;36:1761-70.